Provided by Tiger Fintech (Singapore) Pte. Ltd.

Omeros

8.42
+0.56007.12%
Post-market: 8.420.00000.00%16:23 EDT
Volume:373.07K
Turnover:3.12M
Market Cap:487.94M
PE:-3.71
High:8.54
Open:8.02
Low:7.94
Close:7.86
Loading ...

Company Profile

Company Name:
Omeros
Exchange:
NASDAQ
Establishment Date:
1994
Employees:
198
Office Location:
The Omeros Building,201 Elliott Avenue West,Seattle,Washington,United States
Zip Code:
98119
Fax:
- -
Introduction:
Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, complement-mediated diseases, cancers, and addictive and compulsive disorders. The company's clinical programs include Narsoplimab (OMS721/MASP-2) that has completed pivotal studies for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (HSCT-TMA); that is in Phase III clinical trial for immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19. It also develops OMS1029 that is in phase I clinical trials for long-acting second-generation antibody targeting lectin pathway disorders; OMS906 that is in phase Ib clinical trials for Paroxysmal nocturnal hemoglobinuria, complement 3 glomerulopathy, and other alternative pathway disorders; OMS527 that is in phase I clinical trials for addictions and compulsive disorders, and movement disorders; and OMS405 that is in phase II clinical trials for opioid and nicotine addiction. In addition, the company develops MASP-2-small-molecule inhibitors for the treatment of aHUS, HSCT-TMA, and age-related macular degeneration; GPR174 inhibitors and chimeric antigen receptor T-Cell and adoptive T-Cell therapies for various cancers; and G protein-coupled receptors for treating immunologic, immuno-oncologic, metabolic, CNS, cardiovascular, musculoskeletal, and other disorders. Omeros Corporation was incorporated in 1994 and is headquartered in Seattle, Washington.

Directors

Name
Position
Gregory A. Demopulos
President, Chief Executive Officer and Chairman of the Board
Arnold C. Hanish
Director
Diana T. Perkinson
Director
Leroy E. Hood
Director
Peter A. Demopulos
Director
Rajiv Shah
Director
Thomas F. Bumol
Director
Thomas J. Cable
Director

Shareholders

Name
Position
Gregory A. Demopulos
President, Chief Executive Officer and Chairman of the Board
Bruce Meiklejohn
Vice President, Chemistry, Manufacturing and Controls
Catherine A. Melfi
Vice President, Regulatory Affairs & Quality Systems and Chief Regulatory Officer
Christopher S. Bral
Vice President, Nonclinical Development
Daniel G. Kirby
Vice President, Chief Commercial Officer
George A. Gaitanaris
Vice President, Science and Chief Scientific Officer
J. Steven Whitaker
Vice President, Chief Medical Officer
Michael A. Jacobsen
Vice President, Finance, Chief Accounting Officer and Treasurer
Peter B. Cancelmo
Vice President, General Counsel and Secretary
Timothy M. Duffy
Vice President, Business Development
Tina Quinton
Vice President, Patents